Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

MCTD: Is It Just Letters?

Ruth Jessen Hickman, MD  |  December 4, 2024

At a Great Debate session, speakers discussed whether mixed connective tissue disease is a distinct disease entity in rheumatology.

The ABCs of RCTs

Jason Liebowitz, MD, FACR  |  December 4, 2024

At this ACR Convergence 2024 session, experts discussed new and creative ways to design trials to account for real-world scenarios and to produce information relevant to practicing clinicians.

Sunrise, Sunset: A Look Back on the Year in Rheumatology

Jason Liebowitz, MD, FACR  |  December 4, 2024

At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.

FDA Officials Discuss Extrapolation & Confusion Around Pediatric Therapies

Thomas R. Collins  |  December 3, 2024

A session at ACR Convergence 2024 addressed several recent drug approvals in pediatric rheumatology and a safety update for IL-1/IL-6 inhibitors.

Beth Jonas, MD, Brings Longstanding Workforce Expertise to Committee Chair Role

Vanessa Caceres  |  December 3, 2024

Dr. Jonas has long sought bold and innovative approaches to workforce challenges in rheumatology. As new chair of the Workforce Solutions Committee, she aims to increase the role of advanced practice providers in rheumatology practices and reduce wait times for specialty care.

Top Research in Rheumatoid Arthritis Presented at ACR Convergence 2024

Jeffrey Curtis, MD, MS, MPH  |  December 3, 2024

Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…

Patients with RA in the Setting of Cardiovascular Disease

Samantha C. Shapiro, MD  |  December 3, 2024

How can we best care for our patients from a joint & cardiovascular perspective? That’s the question Christina Charles-Schoeman, MD, MS, professor of medicine and chief, Division of Rheumatology, University of California Los Angeles Medical Center, Santa Monica, Calif., addressed in a session at ACR Convergence 2024.

Where Are We with RA? Prevention, Treatment & Management Challenges

Samantha C. Shapiro, MD  |  December 3, 2024

In this Review Course at ACR Convergence 2024, Iain McInnes, PhD, FRCP, discussed some of the challenges of RA: Remission is drug maintained, multimorbidity abounds, treatment strategies can be complex, & prevention is not yet possible.

ARP Keynote: Empathy, Communication, Collaboration Key to a Good Patient Experience

Thomas R. Collins  |  December 2, 2024

At the ARP Keynote lecture at ACR Convengence 2024, Sandra Mintz, RN, MS, discussed the importance of empathy & trust-building between doctors & their rheumatology patients.

Urate-Lowering Therapy in the Treatment of Patients with Chronic Kidney Disease

Summarized from The New England Journal of Medicine  |  December 2, 2024

In a new-patient consultation for joint pain, you see a 75-year-old man with a history of dementia, stage 3a chronic kidney disease (CKD) and nephrolithiasis. He has a uric acid level of 7.5 mg/dL. His medication list includes 300 mg daily allopurinol. What is NOT an indication for allopurinol? CKD-FIX Elevated serum urate levels are…

  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences